Literature DB >> 31612544

Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand disease.

Karon Abe1, Brandi Dupervil1, Sarah H O'Brien2, Meredith Oakley1, Roshni Kulkarni3, Joan Cox Gill4, Vanessa Byams1, Michael J Soucie1.   

Abstract

There are limited observational studies among children diagnosed with von Willebrand Disease (VWD). We analyzed differences in bleeding characteristics by sex and type of VWD using the largest reported surveillance database of children with VWD (n = 2712), ages 2 to 12 years old. We found that the mean ages of first bleed and diagnosis were lowest among children with type 3 VWD. It was even lower among boys than girls among all VWD types, with statistically significant difference among children with type 1 or type 3 VWD. Children with type 3 VWD also reported higher proportions of ever having a bleed compared to other VWD types, with statistically higher proportions of boys compared to girls reporting ever having a bleed with type 1 and type 2 VWD. A similar pattern was observed with the use of treatment product, showing higher usage among type 3 VWD, and among boys than girls with type 1 and type 2 VWD. While there were no differences in life quality or in well-being status by sex, children with type 3 VWD showed a greater need for mobility assistance compared to children with type 1 and type 2 VWD. In an adjusted analysis among children with type 1 VWD, boys showed a significant association of ever bleeding [hazard ratio 1.4; P-value <.001)] compared to girls. Understanding phenotypic bleeding characteristics, well-being status, treatment, and higher risk groups for bleeding among pre-adolescent children with VWD will aid physicians in efforts to educate families about bleeding symptoms.
© 2019 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2019        PMID: 31612544      PMCID: PMC9125340          DOI: 10.1002/ajh.25656

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   13.265


  23 in total

1.  The power of a standardized bleeding score in diagnosing paediatric type 1 von Willebrand's disease and platelet function defects.

Authors:  P D Marcus; K G Nire; L Grooms; J Klima; S H O'Brien
Journal:  Haemophilia       Date:  2010-09-22       Impact factor: 4.287

2.  The universal data collection surveillance system for rare bleeding disorders.

Authors:  J Michael Soucie; Sally McAlister; Ann McClellan; Meredith Oakley; Ying Su
Journal:  Am J Prev Med       Date:  2010-04       Impact factor: 5.043

Review 3.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

4.  Bleeding spectrum in children with moderate or severe von Willebrand disease: Relevance of pediatric-specific bleeding.

Authors:  Yvonne V Sanders; Karin Fijnvandraat; Johan Boender; Evelien P Mauser-Bunschoten; Johanna G van der Bom; Joke de Meris; Frans J Smiers; Bernd Granzen; Paul Brons; Rienk Y J Tamminga; Marjon H Cnossen; Frank W G Leebeek
Journal:  Am J Hematol       Date:  2015-11-17       Impact factor: 10.047

5.  The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A.

Authors:  J M Soucie; C Wang; A Siddiqi; R Kulkarni; M Recht; B A Konkle
Journal:  Haemophilia       Date:  2011-03       Impact factor: 4.287

6.  Epidemiological investigation of the prevalence of von Willebrand's disease.

Authors:  F Rodeghiero; G Castaman; E Dini
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

7.  von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).

Authors:  W L Nichols; M B Hultin; A H James; M J Manco-Johnson; R R Montgomery; T L Ortel; M E Rick; J E Sadler; M Weinstein; B P Yawn
Journal:  Haemophilia       Date:  2008-03       Impact factor: 4.287

8.  Prospective evaluation of a pediatric bleeding questionnaire and the ISTH bleeding assessment tool in children and parents in routine clinical practice.

Authors:  C Bidlingmaier; V Grote; U Budde; M Olivieri; K Kurnik
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

9.  Moderate to vigorous physical activity and sedentary time and cardiometabolic risk factors in children and adolescents.

Authors:  Ulf Ekelund; Jian'an Luan; Lauren B Sherar; Dale W Esliger; Pippa Griew; Ashley Cooper
Journal:  JAMA       Date:  2012-02-15       Impact factor: 56.272

10.  Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study.

Authors:  K P M van Galen; Y V Sanders; U Vojinovic; J Eikenboom; M H Cnossen; R E G Schutgens; J G van der Bom; K Fijnvandraat; B A P Laros-Van Gorkom; K Meijer; F W G Leebeek; E P Mauser-Bunschoten
Journal:  Haemophilia       Date:  2015-04-09       Impact factor: 4.287

View more
  1 in total

1.  Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders.

Authors:  F Atiq; J L Saes; M C Punt; K P M van Galen; R E G Schutgens; K Meijer; M H Cnossen; B A P Laros-Van Gorkom; M Peters; L Nieuwenhuizen; M J H A Kruip; J de Meris; J G van der Bom; F J M van der Meer; K Fijnvandraat; I C Kruis; W L van Heerde; H C J Eikenboom; Frank W G Leebeek; S E M Schols
Journal:  EClinicalMedicine       Date:  2021-01-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.